Table 1 Patient characteristics
Variable | All SCT patients (n=278), total 299 SCT | |
|---|---|---|
Sex | Male/female | 147/131 |
Age (years) | Median (range) | 46 (17–69) |
Over/under 55 | 91/187 | |
Disease | AML/MDS/ALL/ML/ATL/CML/AA | 102/30/39/62/22/12/8 |
Lymphoid malignancy Y (with RTX)/N | 123 (31)/155 | |
SCT risk | High/standard | 158/141 |
Disease status | Progressive/controlled | 95/204 |
Previous allo-SCT | Y/N | 34/265 |
Donor source | Related/unrelated-BM/CB | 118/130/51 |
HLA allele mismatch (excluding CB) Y/N | 52/197 | |
Conditioning | MAC (TBI Y/N) | 164 (136/28) |
RIST (TBI Y/N) | 135 (92/43) | |
aGVHD prophylaxis | CsA/FK506 based | 60/239 |
+MTX/+MMF/Both | 190/16/46 | |
Pre-SCT IgG (mg/dL) | Median (range) | 973 (140–2271) |
Under/over 800 | 101/198 | |
Follow-up (day) | Median (range) | 1968 (98–4724) |
